From- Fondazione Per La Ricerca Ospedale Di Bergamo- Ets

This study follows 319 adults with polycythemia vera (a rare blood cancer) who are taking ropeginterferon alfa-2b as part of their normal care. Researchers want to see how many people can take the drug without major side effects and how well it controls their blood counts. The go…